Loading...

Ascletis Pharma

BST:2VJ
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2VJ
BST
HK$7B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ascletis Pharma Inc., an investment holding company, focuses on the development and commercialization of various drugs in the People’s Republic of China and internationally. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
2VJ Share Price and Events
7 Day Returns
0%
BST:2VJ
2.6%
DE Biotechs
2.4%
DE Market
1 Year Returns
-
BST:2VJ
2.4%
DE Biotechs
-10.2%
DE Market
2VJ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ascletis Pharma (2VJ) 0% 0% - - - -
DE Biotechs 2.6% -5.4% -7.6% 2.4% 69.9% 78.7%
DE Market 2.4% -3.1% -7.1% -10.2% 26.1% 51.3%
1 Year Return vs Industry and Market
  • No trading data on 2VJ.
  • No trading data on 2VJ.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Ascletis Pharma's competitors could be found in our database.

Value

 Is Ascletis Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ascletis Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ascletis Pharma.

BST:2VJ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:2VJ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.83
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.827 (1 + (1- 25%) (0%))
0.827
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.827 * 9.46%)
8.36%

Discounted Cash Flow Calculation for BST:2VJ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ascletis Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:2VJ DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (CNY, Millions) 140.00 36.00 42.48 49.70 57.65
Source Analyst x1 Analyst x1 Est @ 18%, capped from 78.1% Est @ 17%, capped from 78.1% Est @ 16%, capped from 78.1%
Present Value
Discounted (@ 8.36%)
129.20 30.66 33.38 36.05 38.59
Present value of next 5 years cash flows CN¥267.87
BST:2VJ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= CN¥57.65 × (1 + 0.54%) ÷ (8.36% – 0.54%)
CN¥741.17
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= CN¥741.17 ÷ (1 + 8.36%)5
CN¥496.03
BST:2VJ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= CN¥267.87 + CN¥496.03
CN¥763.90
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥763.90 / 1,120.69
CN¥0.68
BST:2VJ Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:1672)
1.131
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥0.68 x 1.131
HK$0.77
Non-primary Listing Adjustment Factor 1 share in BST:2VJ represents 0.19408x of SEHK:1672
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.19408x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 0.77 x 0.19408
€0.15
Value per share (EUR) From above. €0.15
Current discount Discount to share price of €1.18
= -1 x (€1.18 - €0.15) / €0.15
-689%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Ascletis Pharma is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ascletis Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ascletis Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:2VJ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in CNY CN¥-0.00
SEHK:1672 Share Price ** SEHK (2018-08-09) in HKD HK$6.08
SEHK:1672 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.885 CN¥5.38
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 28.9x
Germany Market PE Ratio Median Figure of 412 Publicly-Listed Companies 18.12x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ascletis Pharma.

BST:2VJ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:1672 Share Price ÷ EPS (both in CNY)

= 5.38 ÷ -0.00

-1902.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascletis Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ascletis Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ascletis Pharma's expected growth come at a high price?
Raw Data
BST:2VJ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1902.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
107.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.58x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.41x

*Line of best fit is calculated by linear regression .

BST:2VJ PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -1902.33x ÷ 107.5%

-17.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascletis Pharma is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ascletis Pharma's assets?
Raw Data
BST:2VJ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in CNY CN¥1.00
SEHK:1672 Share Price * SEHK (2018-08-09) in HKD HK$6.08
SEHK:1672 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.885 CN¥5.38
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.38x
Germany Market PB Ratio Median Figure of 550 Publicly-Listed Companies 1.89x
BST:2VJ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:1672 Share Price ÷ Book Value per Share (both in CNY)

= 5.38 ÷ 1.00

5.4x

* Primary Listing of Ascletis Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascletis Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ascletis Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ascletis Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ascletis Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
107.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ascletis Pharma expected to grow at an attractive rate?
  • Ascletis Pharma's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Ascletis Pharma's earnings growth is expected to exceed the Germany market average.
  • Ascletis Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:2VJ Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:2VJ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 107.5%
BST:2VJ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 82.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.9%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:2VJ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:2VJ Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1,039 263 319 3
2019-12-31 613 160 197 3
2018-12-31 166 21 -2 3
BST:2VJ Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2018-06-30 142 -171 -2
2018-03-31 91 -210 -40
2017-12-31 53 -198 -54
2016-12-31 33 -12 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ascletis Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Ascletis Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:2VJ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Ascletis Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:2VJ Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31
BST:2VJ Past Financials Data
Date (Data in CNY Millions) EPS *
2018-06-30 -0.00
2018-03-31 -0.09
2017-12-31 -0.12
2016-12-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Ascletis Pharma is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Ascletis Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ascletis Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ascletis Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ascletis Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ascletis Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Ascletis Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ascletis Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ascletis Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ascletis Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:2VJ Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 141.73 -2.34 76.35 133.98
2018-03-31 90.96 -39.76 50.18 126.57
2017-12-31 53.20 -53.94 37.48 114.33
2016-12-31 32.98 -26.81 15.04 62.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ascletis Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ascletis Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ascletis Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ascletis Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ascletis Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ascletis Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ascletis Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ascletis Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ascletis Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ascletis Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ascletis Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ascletis Pharma Company Filings, last reported 4 months ago.

BST:2VJ Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 824.95 0.00 613.08
2018-03-31 799.94 0.00 648.44
2017-12-31 869.83 0.00 751.20
2016-12-31 409.08 0.00 424.58
  • Ascletis Pharma has no debt.
  • Ascletis Pharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if Ascletis Pharma has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Ascletis Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ascletis Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ascletis Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ascletis Pharma dividends. Estimated to be 0.46% next year.
If you bought €2,000 of Ascletis Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ascletis Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ascletis Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:2VJ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:2VJ Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.03 2.00
2019-12-31 0.03 2.00
2018-12-31 0.03 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ascletis Pharma has not reported any payouts.
  • Unable to verify if Ascletis Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ascletis Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ascletis Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ascletis Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ascletis Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ascletis Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ascletis Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ascletis Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Ascletis Pharma has no CEO, or we have no data on them.
Management Team Tenure

Average tenure and age of the Ascletis Pharma management team in years:

0.7
Average Tenure
49
Average Age
  • The average tenure for the Ascletis Pharma management team is less than 2 years, this suggests a new team.
Management Team

Judy Wu

TITLE
VP of Operations & Executive Director
AGE
44

Yuemei Yan

TITLE
VP & Director of Sales
AGE
48
TENURE
2 yrs

Kristjan Gudmundsson

TITLE
Senior Consultant & Head of Discovery
AGE
50
TENURE
5.5 yrs

George Hill

TITLE
Senior Consultant & Chief Medical Advisor
AGE
68
TENURE
0.7 yrs

Lok Yim

TITLE
Joint Company Secretary
TENURE
0.4 yrs

Jianjiong Wang

TITLE
Joint Company Secretary & Vice Director of General Affairs
AGE
43
TENURE
0.6 yrs

Joshua Zhongbao Ling

TITLE
Vice President of Finance
TENURE
0.3 yrs

Yi Chen

TITLE
Vice President
AGE
54
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Ascletis Pharma board of directors in years:

0.6
Average Tenure
44
Average Age
  • The average tenure for the Ascletis Pharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Judy Wu

TITLE
VP of Operations & Executive Director
AGE
44
TENURE
0.7 yrs

Jiong Gu

TITLE
Independent Non-Executive Director
AGE
46
TENURE
0.6 yrs

Lin Hua

TITLE
Independent Non-Executive Director
AGE
44
TENURE
0.6 yrs

Ru Ji

TITLE
Independent Non-Executive Director
AGE
54
TENURE
0.6 yrs

Yizhen Wei

TITLE
Independent Non-Executive Director
AGE
43
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Max Price (€) Value (€)
25. Oct 18 Buy GIC Pte. Ltd. Company 24. Oct 18 24. Oct 18 211,000 €0.70 €146,925.62
02. Oct 18 Buy Goldman Sachs Group, Investment Banking and Securities Investments Company 26. Sep 18 26. Sep 18 254,000 €0.85 €215,263.23
X
Management checks
We assess Ascletis Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ascletis Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Ascletis Pharma Inc., an investment holding company, focuses on the development and commercialization of various drugs in the People’s Republic of China and internationally. It provides Ganovo, a direct-acting anti-viral agent and NS3/4A protease inhibitor for hepatitis C virus (HCV) cure. The company’s products also include Ravidasvir that has completed Phase III clinical trials for the treatment of HCV; ASC21, a HCV NS5B nucleotide polymerase inhibitor; ASC09, a protease inhibitor that has completed Phase IIA clinical trials to treat human immunodeficiency virus type-1 infections; and ASC06, which has completed Phase I clinical trials for treating liver cancer. In addition, it is developing therapies that are in pre-clinical trials to treat hepatitis B virus and non-alcoholic steatohepatitis. The company was incorporated in 2014 and is headquartered in Hangzhou, the People’s Republic of China.

Details
Name: Ascletis Pharma Inc.
2VJ
Exchange: BST
Founded: 2014
HK$763,154,049
1,120,685,000
Website: http://www.ascletis.com
Address: Ascletis Pharma Inc.
Building No. 4, Floor 18,
Gemini International,
Hangzhou,
Zhejiang Province, China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 1672 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 01. Aug 2018
DB 2VJ Ordinary Shares Deutsche Boerse AG DE EUR 01. Aug 2018
BST 2VJ Ordinary Shares Boerse-Stuttgart DE EUR 01. Aug 2018
Number of employees
Current staff
Staff numbers
269
Ascletis Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/06 19:19
End of day share price update: 2018/08/09 00:00
Last estimates confirmation: 2018/09/27
Last earnings filing: 2018/09/20
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.